Compare Stocks

Hemostemix CVE:HEM

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Kane Biotech CVE:KNE

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

AdvisorShares Q Portfolio Blended Allocation ETF NYSEARCA:QPT

ProShares Short Basic Materials NYSEARCA:SBM

ProShares Short Basic Materials (the Fund) seeks daily investment results that correspond to the inverse (opposite) of the daily performance of Dow Jones U.S. Basic Materials Index (the Index). The Index measures the performance of the basic materials industry of the United States equity market. The Fund invests in derivatives as a substitute for directly shorting stocks in order to gain inverse exposure to the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. The Fund also invests in short-term cash instruments that have terms to maturity of less than 397 days and exhibit credit profiles. ProShare Advisors LLC is the investment advisor of the Fund.